The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Epcoritamab + R2 or epcoritamab maintenance in 1L FL: 3-year outcomes from EPCORE NHL-2 arms 6 & 7
In this video, Lori Leslie, MD, Hackensack Meridian Mountainside Medical Center, Montclair, NJ, presents the updated long-term results from arms 6 and 7 of the EPCORE NHL-2 trial (NCT04663347). Both arms enrolled patients with previously untreated (1L) follicular lymphoma (FL), with arm 6 evaluating the efficacy of fixed-duration epcoritamab with rituximab and lenalidomide (R2) and arm 7 investigating epcoritamab maintenance following standard of care (SOC) induction. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
